Seminal fluid characterization for male fertility and prostate cancer: Kallikrein-related serine proteases and whole proteome approaches

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 1, 2007, Pages 87-99

  Veveris Lowe, Tara L ^a   Kruger, Sarah J ^a   Walsh, Terry ^a   Gardiner, Robert A ^b   Clements, Judith A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Fertility; Kallikrein related; Prostate cancer; Proteomics; Seminal fluid; Serine protease

Indexed keywords

BIOLOGICAL MARKER; FIBRONECTIN; KALLIKREIN; KALLIKREIN 10; KALLIKREIN 11; KALLIKREIN 13; KALLIKREIN 14; KALLIKREIN 2; KALLIKREIN 3; KALLIKREIN 4; KALLIKREIN 5; KALLIKREIN 6; NEUROPSIN; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEOME; SEMENOGELIN; SERINE PROTEINASE; TISSUE KALLIKREIN; UNCLASSIFIED DRUG; ZINC;

DIAGNOSTIC VALUE; EJACULATION; ENZYME ACTIVITY; EPITHELIUM CELL; GENE; HUMAN; KLK GENE; MALE; MALE FERTILITY; MULTIGENE FAMILY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEOMICS; REVIEW; SEMINAL PLASMA; URETHRA;

ANIMALS; FERTILITY; HUMANS; KALLIKREINS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEOME; SEMEN; TUMOR MARKERS, BIOLOGICAL;

EID: 33846615962     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-958467     Document Type: Review

References (173)

1. Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000;276:125-133
2. Yousef GM, Luo LY, Diamandis EP. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res 1999;19:2843-2852
3. Harvey TJ, Hooper JD, Myers SA, et al. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000;275:37397-37406
4. Gan L, Lee I, Smith R, et al. Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 2000;257:119-130
5. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004;41:265-312
6. Lundwall A, Band V, Blaber M, et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006;387:637-641
7. Dong Y, Bui LT, Odorico DM, et al. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer 2005;12:875-889
8. Tan OL, Whitbread AK, Clements JA, Dong Y. Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? Biol Chem 2006;387:697-705
9. Lovgren J, Valtonen-Andre C, Marsal K, Lilja H, Lundwall A. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 1999;20:348-355
10. Wang MC, Papsidero LD, Kuriyama M, et al. Prostate antigen: a new potential marker for prostatic cancer. Prostate 1981;2:89-96
11. Clements JA, Merritt T, Devoss K, et al. Inactive free: total prostate specific antigen ratios in ejaculate from men with suspected and known prostate cancer, compared with young control men. BJU Int 2000;86:453-458
12. Sensabaugh GF, Blake ET. Seminal plasma protein p30: simplified purification and evidence for identity with prostate specific antigen. J Urol 1990;144:1523-1526
13. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two dosely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368
14. Stenman U, Finne P, Zhang W, Leinonen J. Prostate-specific antigen and other prostate cancer markers. Urology 2000;56:893-898
15. Bindukumar B, Kawinski E, Cherrin C, et al. Two step procedure for purification of enzymatically active prostate-specific antigen from seminal plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:113-120
16. Fortier AH, Holaday JW, Liang H, et al. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 2003;56:212-219
17. Qian Y, Sensibar JA, Zelner DJ, et al. Two-dimensional gel electrophoresis detects prostate-specific antigen-alpha1-antichymotrypsin complex in serum but not in prostatic fluid. Clin Chem 1997;43:352-359
18. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994;220: 45-53
19. Espana F, Gilabert J, Estelles A, et al. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991;64:309-320
20. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170
21. Fink E, Schill WB, Fiedler F, et al. Tissue kallikrein of human seminal plasma is secreted by the prostate gland. Biol Chem Hoppe Seyler 1985;366:917-924
22. Geiger R, Clausnitzer B. Isolation of an enzymatically active tissue kallikrein from human seminal plasma by immunoaffinity chromatography. Hoppe Seylers Z Physiol Chem 1981;362:1279-1283
23. Obiezu CV, Soosaipillai A, Jung K, et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 2002;48:1232-1240
24. Obiezu CV, Shan SJ, Soosaipillai A, et al. Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin Chem 2005;51: 1432-1442
25. Yousef GM, Polymeris ME, Grass L, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958-3965
26. Diamandis EP, Yousef GM, Soosaipillai AR, et al. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 2000;33:369-375
27. Kishi T, Grass L, Soosaipillai A, Shimizu-Okabe C, Diamandis EP. Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin Chem 2003;49:87-96
28. Luo LY, Grass L, Howarth DJ, et al. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 2001;47:237-246
29. Nakamura T, Mitsui S, Okui A, et al. Alternative splicing isoforms of hippostasin (PRSS20/KLK11) in prostate cancer cell lines. Prostate 2001;49:72-78
30. Diamandis EP, Okui A, Mitsui S, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002;62:295-300
31. Luo LY, Shan SJ, Elliott MB, Soosaipillai A, Diamandis EP. Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. Clin Cancer Res 2006;12:742-750
32. Kapadia C, Chang A, Sotiropoulou G, et al. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem 2003;49:77-86
33. Borgono CA, Grass L, Soosaipillai A, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63:9032-9041
34. Deperthes D, Chapdelaine P, Tremblay RR, et al. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1995;1245:311-316
35. Fink E, Schill WB. Tissue kallikrein in human seminal plasma. Adv Exp Med Biol 1983;156(pt B):1175-1180
36. Frenette G, Deperthes D, Tremblay RR, Lazure C, Dube JY. Purification of enzymatically active kallikrein hK2 from human seminal plasma. Biochim Biophys Acta 1997;1334: 109-115
37. Heeb MJ, Espana F. Alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. Blood Cells Mol Dis 1998;24:412-419
38. Ecke S, Geiger M, Resch I, et al. Inhibition of tissue kallikrein by protein C inhibitor. Evidence for identity of protein C inhibitor with the kallikrein binding protein. J Biol Chem 1992;267:7048-7052
39. Espana F, Fink E, Sanchez-Cuenca J, et al. Complexes of tissue kallikrein with protein C inhibitor in human semen and urine. Eur J Biochem 1995;234:641-649
40. Schedlich LJ, Bennetts BH, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987;6:429-437
41. Deperthes D, Frenette G, Brillard-Bourdet M, et al. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 1996;17:659-665
42. Luo LY, Jiang W. Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Biol Chem 2006; 387:813-816
43. Kapadia C, Yousef GM, Mellati AA, et al. Complex formation between human kallikrein 13 and serum protease inhibitors. Clin Chim Acta 2004;339:157-167
44. Obiezu CV, Michael IP, Levesque MA, Diamandis EP. Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Biol Chem 2006;387:749-759
45. Magklara A, Mellati AA, Wasney GA, et al. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 2003;307:948-955
46. Michael IP, Pampalakis G, Mikolajczyk SD, et al. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J Biol Chem 2006;281:12743-12750
47. Michael IP, Sotiropoulou G, Pampalakis G, et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 2005;80:14628-14635
48. Hsieh MC, Cooperman BS. Inhibition of prostate-specific antigen (PSA) by alpha(1)-antichymotrypsin: salt-dependent activation mediated by a conformational change. Biochemistry 2002;41:2990-2997
49. Yousef GM, Kapadia C, Polymeris ME, et al. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. Biochim Biophys Acta 2003;1628:88-96
50. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-890
51. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001;40:15341-15348
52. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204
53. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57:3111-3114
54. Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997;238:549-555
55. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997;272:21582-21588
56. Takayama TK, Carter CA, Deng T. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 2001;40:1679-1687
57. Mikolajczyk SD, Millar LS, Marker KM, et al. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur J Biochem 1997; 246:440-446
58. Denmeade SR, Lovgren J, Khan SR, Lilja H, Isaacs JT. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate 2001;48:122-126
59. Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 2005;124:198-203
60. Little SP, Dixon EP, Norris F, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem 1997;272:25135-25142
61. Sotiropoulou G, Rogakos V, Tsetsenis T, et al. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol Res 2003;13:381-391
62. Auger J, Serres C, Wolf JP, Jouannet P. Sperm motility and fertilization. Contracept Fertil Sex 1994;22:314-318
63. Elzanaty S, Richthoff J, Malm J, Giwercman A. The impact of epididymal and accessory sex gland function on sperm motility. Hum Reprod 2002;17:2904-2911
64. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987;80: 281-285
65. Lilja H, Laurell CB. The predominant protein in human seminal coagulate. Scand J Clin Lab Invest 1985;45:635-641
66. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-1903
67. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-763
68. Lee C, Keefer M, Zhao ZW, et al. Demonstration of the role of prostate-specific antigen in semen liquefaction by two-dimensional electrophoresis. J Androl 1989;10:432-438
69. McGee RS, Herr JC. Human seminal vesicle-specific antigen is a substrate for prostate-specific antigen (or P-30). Biol Reprod 1988;39:499-510
70. Lilja H, Abrahamsson PA, Lundwall A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem 1989;264:1894-1900
71. Malm J, Hellman J, Magnusson H, Laurell CB, Lilja H. Isolation and characterization of the major gel proteins in human semen, semenogelin I and semenogelin II. Eur J Biochem 1996;238:48-53
72. Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate 2000;45:132-139
73. Robert M, Gagnon C. Purification and characterization of the active precursor of a human sperm motility inhibitor secreted by the seminal vesicles: identity with semenogelin. Biol Reprod 1996;55:813-821
74. Robert M, Gibbs BF, Jacobson E, Gagnon C. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 1997;36:3811-3819
75. Akiyama K, Nakamura K, Tsuda R, et al. The chymotrypsin-like activity of human prostate-specific antigen, g-seminoprotein. FEBS Lett 1987;225:168-172
76. Li CH, Hammonds RG Jr, Ramasharma K, Chung D. Human seminal alpha inhibins: isolation, characterization, and structure. Proc Natl Acad Sci USA 1985;82:4041-4044
77. Kausler W, Spiteller G. Analysis of peptides of human seminal plasma by mass spectrometry. Biol Mass Spectrom 1992;21:567-575
78. de Lamirande E, Yoshida K, Yoshiike TM, Iwamoto T, Gagnon C. Semenogelin, the main protein of semen coagulum, inhibits human sperm capacitation by interfering with the superoxide anion generated during this process. J Androl 2001;22:672-679
79. Robert M, Gagnon C. Sperm motility inhibitor from human seminal plasma: association with semen coagulum. Hum Reprod 1995;10:2192-2197
80. Bourgeon F, Evrard B, Brillard-Bourdet M, et al. Involvement of semenogelin-derived peptides in the antibacterial activity of human seminal plasma. Biol Reprod 2004;70: 768-774
81. Lovgren J, Airas K, Lilja H. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur J Biochem 1999;262:781-789
82. Kapadia C, Ghosh MC, Grass L, Diamandis EP. Human kallikrein 13 involvement in extracellular matrix degradation. Biochem Biophys Res Commun 2004;323:1084-1090
83. Rajapakse S, Ogiwara K, Takano N, Moriyama A, Takahashi T. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins. FEBS Lett 2005;579:6879-6884
84. Lwaleed BA, Greenfield R, Stewart A, Birch B, Cooper AJ. Seminal clotting and fibrinolytic balance: a possible physiological role in the male reproductive system. Thromb Haemost 2004;92:752-766
85. Kise H, Nishioka J, Kawamura J, Suzuki K. Characterization of semenogelin II and its molecular interaction with prostate-specific antigen and protein C inhibitor. Eur J Biochem 1996;238:88-96
86. Kishi T, Cloutier SM, Kundig C, Deperthes D, Diamandis EP. Activation and enzymatic characterization of recombinant human kallikrein 8. Biol Chem 2006;387: 723-731
87. Villoutreix BO, Getzoff ED, Griffin JH. A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci 1994;3:2033-2044
88. Robert M, Gagnon C. Semenogelin I: a coagulum forming, multifunctional seminal vesicle protein. Cell Mol Life Sci 1999;55:944-960
89. Jonsson M, Linse S, Frohm B, Lundwall A, Malm J. Semenogelins I and II bind zinc and regulate the activity of prostate-specific antigen. Biochem J 2005;387:447-453
90. Paliouras M, Diamandis EP. The kallikrein world: an update on the human tissue kallikreins. Biol Chem 2006; 387:643-652
91. de Lamirande E, Leclerc P, Gagnon C. Capacitation as a regulatory event that primes spermatozoa for the acrosome reaction and fertilization. Mol Hum Reprod 1997;3:175-194
92. MacDonald RJ, Margolius HS, Erdos EG. Molecular biology of tissue kallikrein. Biochem J 1988;253:313-321
93. Clements JA. The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocr Rev 1989;10:393-419
94. Clements JA. Tissue kallikrein-kinin system. In: Fray JCS, eds. Endocrine Regulation of Electrolyte and Water Balance, Section 7: The Endocrine System, Handbook of Physiology. Vol. III. New York: Oxford University Press; 2000:333-376
95. Fink E, Schill WB, Fiedler F, et al. The tissue kallikreinkinin system in human seminal plasma-biochemical and functional aspects. Adv Exp Med Biol 1986;198(pt A):291-297
96. Fink E, Schill WB, Miska W. Kinin-containing kininogen is present in human seminal plasma. Adv Exp Med Biol 1989;247B:311-315
97. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80
98. Schill WB, Miska W. Possible effects of the kallikrein-kinin system on male reproductive functions. Andrologia 1992; 24:69-75
99. Siems WE, Maul B, Wiesner B, et al. Effects of kinins on mammalian spermatozoa and the impact of peptidolytic enzymes. Andrologia 2003;35:44-54
100. Charlesworth MC, Young CY, Miller VM, Tindall DJ. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl 1999; 20:220-229
101. Deperthes D, Marceau F, Frenette G, et al. Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none. Biochim Biophys Acta 1997;1343:102-106
102. Fichtner J, Graves HC, Thatcher K, Yemoto C, Shortliffe LM. Prostate specific antigen releases a kinin-like substance on proteolysis of seminal vesicle fluid that stimulates smooth muscle contraction. J Urol 1996;155: 738-742
103. Vandekerckhove P, Lilford R, Vail A, Hughes E. Kinin-enhancing drugs for unexplained subfertility in men. Cochrane Database Syst Rev 2000:CD000153
104. Maier U, Hienert G. Tamoxifen and kallikrein in therapy of oligoasthenozoospermia: results of a randomized study. Eur Urol 1990;17:223-225
105. Sterzik K, Strehler E, Abt M, Rosenbusch B. In vitro kallikrein treatment of human spermatozoa: stimulation of sperm penetration into zona-free hamster eggs depends on the quality of initial semen parameters but not on constituents of the kallikrein-kinin system in seminal plasma. J Urol 1994;151:1712-1714
106. Glezerman M, Lunenfeld E, Potashnik G, et al. Efficacy of kallikrein in the treatment of oligozoospermia and asthenozoospermia: a double-blind trial. Fertil Steril 1993;60: 1052-1056
107. Keck C, Behre HM, Jockenhovel F, Nieschlag E. Ineffectiveness of kallikrein in treatment of idiopathic male infertility: a double-blind, randomized, placebo-controlled trial. Hum Reprod 1994;9:325-329
108. Yeung CH, Spier B, Cooper TG, Nacke P, Nieschlag E. The effect of bradykinin and the bradykinin antagonist Hoe 140 on kinematic parameters of human spermatozoa. Int J Androl 1996;19:143-149
109. Tremblay RR, Coulombe E, Cloutier S, et al. Assessment of the trypsin-like human prostatic kallikrein, also known as hK2, in the seminal plasma of infertile men: respective contributions of an ELISA procedure and of Western blotting. J Lab Clin Med 1998;131:330-335
110. Ahlgren G, Rannevik G, Lilja H. Impaired secretory function of the prostate in men with oligo-asthenozoospermia. J Androl 1995;16:491-498
111. Lynne CM, Aballa TC, Wang TJ, et al. Serum and semen prostate specific antigen concentrations are different in young spinal cord injured men compared to normal controls. J Urol 1999;162:89-91
112. Elzanaty S, Malm J, Giwercman A. Visco-elasticity of seminal fluid in relation to the epididymal and accessory sex gland function and its impact on sperm motility. Int J Androl 2004;27:94-100
113. Mifsud A, Choon AT, Fang D, Yong EL. Prostate-specific antigen, testosterone, sex-hormone binding globulin and androgen receptor CAG repeat polymorphisms in subfertile and normal men. Mol Hum Reprod 2001;7:1007-1013
114. Glander HJ, Kratzsch J, Weisbrich C, Birkenmeier G. Insulin-like growth factor-I and alpha 2-macroglobulin in seminal plasma correlate with semen quality. Hum Reprod 1996;11:2454-2460
115. Fielder PJ, Rosenfeld RG, Graves HC, et al. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul 1994;4: 164-172
116. Rehault S, Monget P, Mazerbourg S, et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 2001;268:2960-2968
117. Cohen P, Graves HC, Peehl DM, et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-1053
118. Matsumura M, Bhatt AS, Andress D, et al. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 2005;62:1-13
119. Comhaire FH, Vermeulen L, Pieters O. Study of the accuracy of physical and biochemical markers in semen to detect infectious dysfunction of the accessory sex glands. J Androl 1989;10:50-53
120. Wolff H, Bezold G, Zebhauser M, Meurer M. Impact of clinically silent inflammation on male genital tract organs as reflected by biochemical markers in semen. J Androl 1991; 12:331-334
121. von der Kammer H, Scheit KH, Weidner W, Cooper TG. The evaluation of markers of prostatic function. Urol Res 1991;19:343-347
122. Hammerer PG, Kattan MW, Mottet N, Prayer-Galetti T. Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer. BJU Int 2006;98;11-19
123. Lilja H. Biology of prostate-specific antigen. Urology 2003;62;27-33
124. Kwiatkowski MK, Recker F, Piironen T, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 1998;52:360-365
125. Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. J Urol 2003;170:1169-1174
126. Haese A, Graefen M, Becker C, et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 2003;54:181-186
127. Nakamura T, Scorilas A, Stephan C, et al. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 2003;63:6543-6546
128. Stephan C, Meyer HA, Cammann H, et al. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biol Chem 2006;387:801-805
129. Veveris-Lowe TL, Lawrence MG, Collard RL, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005;12:631-643
130. Stephan C, Yousef GM, Scorilas A, et al. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J Urol 2003;169:361-364
131. Yousef GM, Stephan C, Scorilas A, et al. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 2003;56: 287-292
132. Banez LL, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003; 170:442-446
133. Adam BL, Vlahou A, Semmes OJ, Wright GL Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 2001;1:1264-1270
134. Qu Y, Adam BL, Yasui Y, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-1843
135. Petricoin EF III, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-1578
136. Lehrer S, Roboz J, Ding H, et al. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003; 92:223-225
137. Banez LL, Srivastava S, Moul JW. Proteomics in prostate cancer. Curr Opin Urol 2005;15:151-156
138. Wright ME, Han DK, Aebersold R. Mass spectrometry-based expression profiling of clinical prostate cancer. Mol Cell Proteomics 2005;4:545-554
139. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-378
140. Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-112
141. Qin S, Ferdinand AS, Richie JP, et al. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 2005;5:3183-3192
142. Solassol J, Marin P, Demettre E, et al. Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Anal Biochem 2005;338:26-31
143. Lam YW, Mobley JA, Evans JE, Carmody JF, Ho SM. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005;5:2927-2938
144. Jung K, Reiche J, Boehme A, et al. Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer. Clin Chem 2004;50:2292-2301
145. Ornstein DK, Gillespie JW, Paweletz CP, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 2000; 21:2235-2242
146. Ahram M, Best CJ, Flaig MJ, et al. Proteomic analysis of human prostate cancer. Mol Carcinog 2002;33:9-15
147. Partin AW, Briggman JV, Subong EN, et al. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins. Urology 1997;50:800-808
148. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002;50:54-63
149. Starita-Geribaldi M, Poggioli S, Zucchini M, et al. Mapping of seminal plasma proteins by two-dimensional gel electrophoresis in men with normal and impaired spermatogenesis. Mol Hum Reprod 2001;7:715-722
150. Bohring C, Krause E, Habermann B, Krause W. Isolation and identification of sperm membrane antigens recognized by antisperm antibodies, and their possible role in immunological infertility disease. Mol Hum Reprod 2001; 7:113-118
151. Edwards JJ, Tollaksen SL, Anderson NG. Proteins of human semen. I. Two-dimensional mapping of human seminal fluid. Clin Chem 1981;27:1335-1340
152. Ayyagari RR, Fazleabas AT, Dawood MY. Seminal plasma proteins of fertile and infertile men analyzed by two-dimensional electrophoresis. Am J Obstet Gynecol 1987; 157:1528-1533
153. Naaby-Hansen S, Flickinger CJ, Herr JC. Two-dimensional gel electrophoretic analysis of vectorially labeled surface proteins of human spermatozoa. Biol Reprod 1997;56:771-787
154. Fung KY, Glode LM, Green S, Duncan MW. A comprehensive characterization of the peptide and protein constituents of human seminal fluid. Prostate 2004;61:171-181
155. Pilch B, Mann M. Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol 2006;7:R40
156. Utleg AG, Yi EC, Xie T, et al. Proteomic analysis of human prostasomes. Prostate 2003;56:150-161
157. Tsai YC, Harrison HH, Lee C, et al. Systematic characterization of human prostatic fluid proteins with two-dimensional electrophoresis. Clin Chem 1984;30:2026-2030
158. Guevara J Jr, Herbert BH, Lee C. Two-dimensional electrophoretic analysis of human prostatic fluid proteins. Cancer Res 1985;45:1766-1771
159. Grover PK, Resnick MI. High resolution two-dimensional electrophoretic analysis of urinary proteins of patients with prostatic cancer. Electrophoresis 1997;18:814-818
160. Grover PK, Resnick MI. Analysis of prostatic fluid: evidence for the presence of a prospective marker for prostatic cancer. Prostate 1995;26:12-18
161. Rehman I, Azzouzi AR, Catto JW, et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004; 64:1238-1243
162. le Coutre J, Whitelegge JP, Gross A, et al. Proteomics on full-length membrane proteins using mass spectrometry. Biochemistry 2000;39:4237-4242
163. Wall DB, Kachman MT, Gong S, et al. Isoelectric focusing nonporous RP HPLC: a two-dimensional liquid-phase separation method for mapping of cellular proteins with identification using MALDI-TOF mass spectrometry. Anal Chem 2000;72:1099-1111
164. Opiteck GJ, Ramirez SM, Jorgenson JW, Moseley MA III. Comprehensive two-dimensional high-performance liquid chromatography for the isolation of overexpressed proteins and proteome mapping. Anal Biochem 1998;258:349-361
165. Zhang Z, Smith DL, Smith JB. Multiple separations facilitate identification of protein variants by mass spectrometry. Proteomics 2001;1:1001-1009
166. Chong BE, Yan F, Lubman DM, Miller FR. Chromatofocusing nonporous reversed-phase high-performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry of proteins from human breast cancer whole cell lysates: a novel two-dimensional liquid chromatography/mass spectrometry method. Rapid Commun Mass Spectrom 2001;15:291-296
167. Chong BE, Hamler RL, Lubman DM, et al. Differential screening and mass mapping of proteins from premalignant and cancer cell lines using nonporous reversed-phase HPLC coupled with mass spectrometric analysis. Anal Chem 2001;73:1219-1227
168. Wang H, Hanash S. Multi-dimensional liquid phase based separations in proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2003;787:11-18
169. Larmann JP Jr, Lemmo AV, Moore AW Jr, Jorgenson JW. Two-dimensional separations of peptides and proteins by comprehensive liquid chromatography-capillary electrophoresis. Electrophoresis 1993;14:439-447
170. Zhu K, Kim J, Yoo C, Miller FR, Lubman DM. High sequence coverage of proteins isolated from liquid separations of breast cancer cells using capillary electrophoresis-time-of-flight MS and MALDI-TOF MS mapping. Anal Chem 2003;75:6209-6217
171. Zhu K, Miller FR, Barder TJ, Lubman DM. Identification of low molecular weight proteins isolated by 2-D liquid separations. J Mass Spectrom 2004;39:770-780
172. Hamler RL, Zhu K, Buchanan NS, et al. A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics 2004;4:562-577
173. Kruger SR, Gardiner J, Clements JA, Walsh T. Proteomic analysis of samples obtained from men with and without prostate cancer using the Proteomelab PF-2D system. Smart Solutions for Life Sciences. San Diego, CA: Beckman Coulter; 2004:12-13